More on HALO
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $58.79 |
|
|||
| Open | $58.79 | ||||
| 52 Wk High | $18.39 | ||||
| 52 Wk Low | $6.96 | ||||
| Day High | $58.79 | ||||
| Day Low | $58.79 | ||||
| P/E | N/A | ||||
| EPS | $-0.58 | ||||
| Volume | 281 | ||||
- Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating
- Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous DARZALEX-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligi
- European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
- Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous RYBREVANT
- European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Henderson Jeffrey William
- Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo with ENHANZE
- Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
- Form 8-K HALOZYME THERAPEUTICS, For: Mar 17
- Form ARS HALOZYME THERAPEUTICS, For: Dec 31
Entities mentioned with HALO
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- S3 | View Related Stories »
- 13G | View Related Stories »
- Stock Buyback | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
